Company: CERO
Filing Date: 2025-08-22
Form Type: 10-Q
Source: 0001213900-25-079898
Chunk: 214

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 10-Q
Item: Item 8
Chunk 214
---
 we recorded deemed dividends of $24,965,000, and in connection with the adjustment in
the exercise price of Series C Common Warrants, we recorded deemed dividends of $84,000. Accordingly, for the six months ended June 30,
2025 and 2024, net loss attributable to common stockholders amounted to $35,572,000, or $(107.60) per common share, and $4,748,348, or
$(604.19) per common share, respectively.

Liquidity
and Capital Resources

Capital
Requirements

Predecessor
and the Company have not generated any revenue from any source and the Company does not expect to generate revenue for at least the next
few years. If the Company fails to complete the timely development of, or fails to obtain regulatory approval for, its product candidates,
the ability of the Company to generate future revenue will be adversely affected. The Company does not know when, or if, it will generate
any revenue from its product candidates, and does not expect to generate revenue unless and until the Company obtains regulatory approval
and commercialization of its product candidates.

The
Company expects its expenses to increase significantly in connection with its ongoing activities, particularly as it continues and expands
research, preclinical development, and clinical development to support marketing approval for its product candidates. In addition, if
the Company obtains approval for any of its product candidates, the Company expects to incur significant commercialization expenses related
to sales, marketing, manufacturing and distribution. Furthermore, the Company expects to incur additional costs associated with operating
as a public company.

The Company, therefore, anticipates that substantial additional funding
will be needed in connection with its continuing operations. As of June 30, 2025, the Company had approximately $3.2 million in cash
and cash equivalents. The Company intends to devote most of the available cash to the preclinical and clinical development of its product
candidates and public company compliance costs. Based on current business plans, the Company believes that the cash available as of June
30, 2025 will not fund its operations and capital requirements for 12 months after the filing of these unaudited condensed financial statements
for the period ended June 30, 2025. The Company has arranged two equity lines of credit, one providing for the sale of up to 25,000,000
newly issued shares of Common Stock and the other providing for the purchase of up to $17.5 million of Common